Ignite Creation Date:
2024-05-06 @ 8:37 AM
Last Modification Date:
2024-10-26 @ 12:03 PM
Study NCT ID:
NCT02784158
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2018-02-06
First Post:
2016-05-24
Brief Title:
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Sponsor:
Ariad Pharmaceuticals
Organization:
Takeda
Study Overview
Official Title:
None
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2018-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to provide brigatinib for those patients with locally advanced andor metastatic patients with ALK NSCLC on an expanded access basis due to their inability to meet eligibility criteria for on-going recruiting trials inability to participate in other clinical trials eg poor performance status lack of geographic proximity or because other medical interventions are not considered appropriate or acceptable
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None